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Wolfram	syndrome	is	an	autosomal-recessive	disorder	characterized	by	insulin-dependent	diabetes	mellitus,	
caused	by	nonautoimmune	loss	of	β	cells,	and	neurological	dysfunctions.	We	have	previously	shown	that	
mutations	in	the	Wolfram	syndrome	1	(WFS1)	gene	cause	Wolfram	syndrome	and	that	WFS1	has	a	protective	
function	against	ER	stress.	However,	it	remained	to	be	determined	how	WFS1	mitigates	ER	stress.	Here	we	
have	shown	in	rodent	and	human	cell	lines	that	WFS1	negatively	regulates	a	key	transcription	factor	involved	
in	ER	stress	signaling,	activating	transcription	factor	6α	(ATF6α),	through	the	ubiquitin-proteasome	pathway.	
WFS1	suppressed	expression	of	ATF6α	target	genes	and	repressed	ATF6α-mediated	activation	of	the	ER	stress	
response	element	(ERSE)	promoter.	Moreover,	WFS1	stabilized	the	E3	ubiquitin	ligase	HRD1,	brought	ATF6α	
to	the	proteasome,	and	enhanced	its	ubiquitination	and	proteasome-mediated	degradation,	leading	to	sup-
pression	of	ER	stress	signaling.	Consistent	with	these	data,	β	cells	from	WFS1-deficient	mice	and	lymphocytes	
from	patients	with	Wolfram	syndrome	exhibited	dysregulated	ER	stress	signaling	through	upregulation	of	
ATF6α	and	downregulation	of	HRD1.	These	results	reveal	a	role	for	WFS1	in	the	negative	regulation	of	ER	
stress	signaling	and	in	the	pathogenesis	of	diseases	involving	chronic,	unresolvable	ER	stress,	such	as	pancre-
atic	β	cell	death	in	diabetes.
Introduction
Productive folding of secretory proteins and degradation of misfolded 
proteins are essential to ensure normal cell function. Both these pro-
cesses occur in the ER. Perturbations in ER function cause an imbal-
ance between these processes, leading to accumulation of misfolded 
and unfolded proteins in the organelle, a state called ER stress. Cells 
cope with ER stress by activating an ER stress signaling network, also 
called the unfolded protein response (UPR). Activation of the UPR 
not only results in the upregulation of gene expression for molecular 
chaperones, but expands the size of the ER, decreases general protein 
translation to reduce the ER workload, and degrades abnormal pro-
teins accumulated in the ER (1, 2). As long as the UPR can mitigate 
ER stress, cells can produce proper amounts of proteins in response to 
the need for them and perform their normal functions.
Activating transcription factor 6α (ATF6α) is 1 of the 3 mas-
ter regulators of the UPR (1). ATF6 encodes a bZIP-containing 
transcription factor localized to the ER membrane (3). Under ER 
stress, the N-terminal DNA binding domain of ATF6α is cleaved 
and released from the ER (3–5). The bZIP domain of ATF6α 
then translocates into the nucleus and upregulates downstream 
target genes, such as BiP and XBP-1, that function in protein 
folding and processing (3, 4, 6). Therefore, deletion of ATF6α 
compromises the secretory pathway during ER stress (7, 8). It 
has been reported that the noncleaved form of ATF6α is unsta-
ble and quickly degraded by the ubiquitin-proteasome pathway 
to prevent hyperactivation of the UPR (9). However, the mecha-
nism underlying this phenomenon has yet to be elucidated.
WFS1, a transmembrane protein localized to the ER (10), has 
previously been shown to be a UPR component that mitigates ER 
stress response in cells (11). Mutations in the gene encoding WFS1 
cause Wolfram syndrome, a genetic form of diabetes, optic atro-
phy, neurodegeneration, and psychiatric illness (12, 13). Recent 
reports also indicated that WFS1 polymorphisms are associated 
with type 2 diabetes (14–16). Accumulating evidence indicates that 
β cell death and neuronal cell dysfunction in Wolfram syndrome 
are attributed to high levels of ER stress signaling in affected cells 
(11, 17–19). However, the function of WFS1 in the UPR has been 
unclear. Here we showed that WFS1 controls a regulatory feed-
back loop of the ER stress signaling network. Activation of the 
ER stress response element (ERSE) by ATF6α was attenuated by 
WFS1 expression. WFS1 recruited ATF6α to an E3 ligase, HRD1, 
and the proteasome, where it enhanced ATF6α degradation, thus 
suppressing the UPR. Inducible overexpression of WFS1 thereby 
decreased expression levels of ATF6α target genes, such as BiP and 
XBP-1. These results indicate that WFS1 has an important func-
tion in the negative regulation of a feedback loop of the ER stress 
signaling network and prevents secretory cells from death caused 
by dysregulation of this signaling pathway.
Results
WFS1 forms an ER stress–mediated complex with ATF6α and suppresses 
its activity. In order to further define the role of WFS1 in the UPR, 
we assessed whether WFS1 expression affects the function of UPR 
Conflict	of	interest: The authors have declared that no conflict of interest exists.
Citation	for	this	article: J Clin Invest. 2010;120(3):744–755. doi:10.1172/JCI39678.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 120   Number 3   March 2010 745
components. Transcriptional activity of a transmembrane transcrip-
tion factor and master regulator of the UPR, ATF6α, is attenuated 
by WFS1 expression. Under ER stress, the N-terminal DNA binding 
domain of ATF6α is cleaved and released from the ER to upregu-
late UPR target genes in the nucleus (3–5). As expected, when full-
length ATF6α was transfected with the ATF6α binding site reporter 
gene ATF6GL3, this reporter was induced 12-fold by ATF6α (20), 
an induction reduced to 3-fold by cotransfection with WFS1 (Fig-
ure 1A). ATF6α has also been shown to strongly activate the BiP/
GRP78 promoter (4). To confirm that WFS1 regulates ATF6α tran-
scriptional activity on the BiP/GRP78 promoter, full-length ATF6α 
or cleaved ATF6α (ΔATF6α) was cotransfected with WFS1 and a rat 
GRP78 promoter reporter gene containing the ER stress response 
element (ERSE). This reporter was induced by both full-length 
ATF6α and ΔATF6α; however, only full-length ATF6α activity was 
suppressed by WFS1 expression (Figure 1A). In addition, full-length 
ATF6α protein expression decreased when it was coexpressed with 
WFS1 (Figure 1B). BiP has previously been shown to anchor full-
length ATF6α to the ER membrane and prevent ATF6α activation 
(6, 21). To compare the ability of WFS1 to suppress ATF6α with that 
of BiP, the GRP78 promoter reporter was cotransfected with full-
length ATF6α and BiP, with full-length ATF6α and WFS1, or with 
full-length ATF6α, BiP, and WFS1. Suppression of ATF6α activity 
by WFS1 was stronger than that by BiP (Figure 1C). Collectively, 
these results indicate that WFS1 suppresses ATF6α transcriptional 
activity before its translocation to the nucleus.
Figure 1
WFS1 interacts with ATF6α in an ER stress–dependent manner and suppresses ATF6α transcriptional activation. (A) COS7 cells were trans-
fected with a full-length ATF6α expression plasmid or ΔATF6α with a WFS1 plasmid together with the following luciferase reporter genes: ATF6α 
binding site reporter gene ATF6GL3, ATF6α mutant site reporter ATF6m1GL3, and GRP78 promoter reporter gene ERSE. Relative intensity 
of luciferase was then measured (n = 3). (B) Protein lysates from the luciferase assay were analyzed by IB using anti-HA (ATF6α), anti-Flag 
(WFS1), and anti-actin antibodies. ATF6α and ΔATF6α are denoted by single and double asterisks, respectively. (C) COS7 cells were transfect-
ed with a full-length ATF6α expression plasmid with a BiP expression plasmid, WFS1 expression plasmid, or WFS1 and BiP expression plasmid 
together with the GRP78 reporter gene (n = 3). (D) An anti-WFS1 antibody was used to IP WFS1 protein from INS1 832/13 cells untreated (UT) 
or treated with the ER stress inducer DTT (1 mM) for 0.5, 1.5, or 3 hours. IPs were then subject to IB analysis using anti-ATF6α, anti-WFS1, and 
anti-actin antibodies (n = 3). (E) INS1 832/13 cells were treated with DTT (1 mM) for 2 hours and then chased in normal media for 0, 1, or 2 hours. 
WFS1 was subjected to IP from cell lysates, and IPs were analyzed by IB using anti-ATF6α, anti-WFS1, and anti-actin antibodies (n = 3).
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Both WFS1 and ATF6α are transmembrane proteins localized to 
the ER (3, 10), raising the possibility that the suppression of the 
ATF6α reporter by WFS1 might be mediated by direct interaction 
between the WFS1 and ATF6α proteins. To confirm this, the asso-
ciation of WFS1 with ATF6α was examined in the pancreatic β cell 
line INS-1 832/13. WFS1 associated with ATF6α under nonstress 
conditions (Figure 1D). To examine whether this interaction was 
maintained during ER stress conditions, the cells were treated with 
the ER stress inducer dithiothreitol (DTT), which caused a disso-
ciation of ATF6α from WFS1 in a time-dependent manner, with 
almost complete dissociation 3 hours after treatment (Figure 1D). 
This ER stress–dependent interaction was also observed in cells 
treated with another ER stress inducer, thapsigargin (Supplemental 
Figure 1; supplemental material available online with this article; 
doi:10.1172/JCI39678DS1). To confirm that this interaction was 
recovered after stress, cells were treated for 2 hours with DTT and 
then chased in normal media. As expected, the interaction of ATF6 
and WFS1 began to recover after a 1-hour chase (Figure 1E). This 
interaction was also seen in the neuronal cell line Neuro2A (Supple-
mental Figure 2). Together, these data suggest that ATF6 is released 
from WFS1 under stress in order to activate its target UPR genes.
WFS1 has a function in the degradation of ATF6α through the ubiquitin-
proteasome pathway. Suppression of ATF6α transcriptional activity 
by WFS1 and the formation of an ATF6α-WFS1 complex led to the 
prediction that WFS1 regulates ATF6α function at the posttrans-
lational level. To test this prediction, we derived a pancreatic β cell 
line, MIN6 cells, stably expressing a shRNA directed against WFS1. 
Full-length as well as nuclear ATF6α protein levels increased approx-
imately 2-fold compared with control cells (Figure 2A). To confirm 
that upregulation of ATF6α protein is directly regulated by WFS1, 
we reintroduced a lentivirus expressing WFS1 into the cells express-
ing shRNA directed against WFS1; ATF6 protein expression levels 
were again reduced when WFS1 was reintroduced (Figure 2A).
ATF6α mRNA was unchanged in the WFS1-knockdown INS-1 
832/13 cells, but ATF6α target genes, such as p58IPK and BiP (7, 8), 
were upregulated as predicted (Supplemental Figure 3). To further 
confirm that this upregulation is directly regulated by ATF6α, we 
suppressed ATF6α expression by siRNA in WFS1 knockdown INS-
1 832/13 cells and then measured expression levels of its major 
target, BiP. Upregulation of BiP by WFS1 inhibition was cancelled 
out by ATF6α inhibition (Supplemental Figure 4).
ATF6α protein levels were also measured in INS-1 832/13 
cells overexpressing WFS1. Full-length and nuclear ATF6α pro-
tein levels were suppressed in these cells, whereas there was no 
significant change in protein levels of the other 2 master regu-
lators of the UPR, IRE1 and PERK (Figure 2B). IRE1 and PERK 
protein expression levels were not decreased even with higher 
levels of WFS1 expression (Supplemental Figure 5). Suppression 
of ATF6α protein expression was also seen in a neuronal cell line 
(Supplemental Figure 6). ATF6 target gene mRNA levels were 
also suppressed in β cells overexpressing WFS1 (Figure 2C). The 
relationship of WFS1 and ATF6 protein expression was found 
to be dose-dependent: increased expression of WFS1 leads to a 
decrease in ATF6 protein expression (Supplemental Figure 7). 
We asked whether this relationship was proteasome dependent. 
Treatment of 2 WFS1-overexpressing cell lines with the pro-
teasome inhibitor MG132 rescued ATF6α protein levels (Figure 
2D). We cloned 2 missense mutants, WFS1 P724L and WFS1 
G695V, and 1 inactivating mutant, WFS1 ins483fs/ter544, from 
patient samples (13). Mutant variants of WFS1 did not affect 
ATF6α protein levels in MIN6 cells expressing shRNA directed 
against WFS1 (Figure 2E and Supplemental Figure 8). This was 
also confirmed in INS-1 832/13 cells expressing the missense 
mutant WFS1 P724L (Figure 2F) and in neuronal cells express-
ing the missense mutant WFS1 G695V (Supplemental Figure 9). 
Although ATF6α weakly interacted WFS1 P724L and WFS1 
G695V, there was no significant decrease in ATF6α protein levels 
in these cells (Figure 2G).
To assess the impact of WFS1 on ATF6α protein degradation, 
cycloheximide experiments were performed. In MIN6 cells express-
ing shRNA directed against WFS1, there was a block in ATF6α 
protein degradation, whereas in cells overexpressing WFS1, there 
was minimal ATF6α protein expression (Figure 3, A and B). WFS1 
could not enhance the degradation of 2 other ER proteins suscep-
tible to misfolding, TCRα and mutant alpha-1-antitrypsin NHK3 
(refs. 22–24 and Supplemental Figure 10), which indicates that 
WFS1 specifically degrades ATF6α protein. WFS1 also enhanced 
the ubiquitination of ATF6α. In cells expressing shRNA directed 
against WFS1, there was a decrease in ATF6α ubiquitination after 
blocking proteasome activity (Figure 3C), whereas in cells over-
expressing WFS1, there was an enhancement of ATF6α ubiqui-
tination (Figure 3D). In Wfs1–/– mouse pancreata, ATF6α protein 
expression was strikingly high compared with control littermate 
pancreata (Figure 3E), indicating that WFS1 functions in ATF6α 
protein expression in vivo. In samples from patients with WFS1 
mutations, there was a higher expression of ATF6α protein com-
pared with control samples (Supplemental Figure 11). Together, 
these results indicate that WFS1 is important for regulating 
ATF6α protein expression. When WFS1 was not present, there was 
increased expression of ATF6α protein and hyperactivation of its 
downstream effectors. This suggests that in response to ER stress, 
ATF6α escapes from WFS1-dependent degradation, is cleaved in 
the Golgi to its active form, and then translocates to the nucleus 
to upregulate its UPR target genes.
These data raised the possibility that WFS1 recruits ATF6α 
to the proteasome for its degradation. As we predicted, WFS1 
formed a complex with the proteasome (Figure 4A). When glyc-
erol-gradient fractionation was performed on ER-isolated lysates, 
the proteasome ATF6α and WFS1 comigrated in the same high–
Figure 2
WFS1 regulates ATF6α protein levels. (A) IB analysis measured 
ATF6α and WFS1 levels in MIN6 cells expressing shGFP (control) or 
shWFS1, as well as in MIN6 cells expressing shWFS1 or expressing 
shWFS1 and rescued with WFS1 (n = 3). (B) IB analysis measuring 
ATF6α, WFS1, IRE1α, and PERK levels in INS1 832/13 cells (treated 
with 2 mM DTT for 3 hours) overexpressing GFP (control) or WFS1 
(n = 3). (C) Quantitative real-time PCR analysis of BiP, total Xbp-1, 
Chop, Ero1-α, Glut2, and Ins2 mRNA levels in INS1 832/13 cells over-
expressing GFP (control) or WFS1 (n = 3). (D) IB analysis of ATF6α 
and WFS1 in COS7 cells transfected with ATF6α-HA or ATF6α-HA and 
WFS1-FLAG at 2 different ratios, and in INS1 832/13 cells expressing 
inducible WFS1 and treated with or without MG132. (E) IB analysis of 
ATF6α and WFS1 in MIN6 cells expressing shWFS1 and transfect-
ed with WT WFS1-FLAG or mutant P724L WFS1-FLAG and G695V 
WFS1-FLAG (n = 3). (F) IB analysis measuring ATF6α and WFS1 lev-
els in INS1 832/13 cells expressing WT WFS1 or P724L WFS1 (n = 3). 
(G) WFS1 was subjected to IP from COS7 cells expressing ATF6α-HA 
or ATF6α-HA with WT, P724L, or G695V WFS1-Flag using an anti-
Flag antibody. IPs and input proteins were analyzed using anti-HA and 
anti-Flag antibodies. **P < 0.01.
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Figure 3
WFS1 enhances ATF6α ubiquitination and degradation. (A) IB analysis measuring ATF6α, WFS1, and actin levels in MIN6 cells stably 
expressing shGFP (control) or shWFS1 treated with 40 μM cycloheximide (CX) for 0, 2, and 4 hours (n = 3). (B) IB analysis measuring 
ATF6α, WFS1, and actin levels in INS1 832/13 cells expressing GFP (control) or WFS1 treated with 40 μM cycloheximide for 0, 2, and 6 hours 
(n = 3). (C) ATF6α was subjected to IP using an anti-ATF6α antibody from an INS1 832/13 cells inducibly expressing shWFS1 (treated for 48 
hours with 2 μM doxycycline) and treated with MG132 (20 μM) for 3 hours. IPs were then subjected to IB with anti-ubiquitin and anti-ATF6α 
antibodies, and input lysates were blotted with anti-ATF6α, anti-WFS1, and anti-actin antibodies (n = 3). (D) ATF6α was subjected to IP 
using an anti-ATF6α antibody, from INS1 832/13 cells overexpressing GFP (control) or WFS1, then treated with MG132 (0.1 μM) overnight. 
IPs were subjected to IB with anti-ubiquitin and anti-ATF6α antibodies. Input lysates were subjected to IB with anti-ATF6α, anti-WFS1, and 
anti-actin antibodies (n = 3). (E) Wfs1–/– and WT littermate mouse pancreata were analyzed by immunohistochemistry using anti-ATF6α and 
anti-insulin antibodies. Scale bars: 50 μm.
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molecular weight fractions, and a complex between them was 
formed (Figure 4, B and C).
WFS1 stabilizes HRD1, which functions as an E3 ligase for ATF6α. 
Because WFS1 is localized to the ER membrane and recruits ATF6α 
to the proteasome, but is not itself an E3 ligase, we searched for 
ER-localized E3 ligases with which WFS1 could interact. A top can-
didate was the ER-resident E3 ligase HRD1, which has a known role 
in ER stress signaling (25, 26). SEL1/HRD3, which has an impor-
tant function in hydroxy-3-methylglutaryl-CoA reductase (HMG-R) 
degradation (27), has been shown to interact with and stabilize 
HRD1 (28), raising the possibility that WFS1 may also have a simi-
lar function and could interact with HRD1. Indeed, WFS1 and 
HRD1 formed a complex (Figure 5A). We next asked whether WFS1 
also plays a role in HRD1 protein expression. Inducible suppression 
of WFS1 in INS-1 832/13 cells expressing shRNA directed against 
WFS1 suppressed HRD1 protein expression (Figures 5B). To test 
the effect of WFS1 on HRD1 protein stability, we performed cyclo-
heximide experiments using MIN6 cells stably expressing shRNA 
directed against WFS1. HRD1 protein expression was significantly 
decreased in WFS1 knockdown cells compared with control cells, 
and it was difficult to measure the stability of HRD1 (Figure 5C).
We further confirmed the effects of WFS1 on HRD1 protein 
expression in vivo using Wfs1–/– mice. As expected from the 
results using β cell lines, HRD1 expression was undetectable in 
islets of Wfs1–/– mice (Figure 5D). In addition, in samples from 
patients with Wolfram syndrome, there was less HRD1 protein 
expression compared with control samples (Supplemental Figure 
12A). HRD1 expression did not affect WFS1 protein expression 
(Supplemental Figure 12B).
We next sought to compare the effects of WT WFS1 and WFS1 
mutants on HRD1 protein expression. Ectopic expression of WT 
WFS1 increased HRD1 protein expression, whereas ectopic expres-
sion of missense and inactivating WFS1 mutants did not increase 
or decrease HRD1 expression (Figure 5E). To determine whether 
WFS1 mutants interact with HRD1, comparable amounts of WT 
and missense mutant WFS1 proteins were expressed together 
with HRD1 in COS7 cells, and the interaction was monitored 
by co-IP. HRD1 interacted with WT WFS1, but not with WFS1 
mutants (Figure 5F). Collectively, these results demonstrated that 
WFS1 stabilizes and enhances the function of the E3 ligase HRD1 
through direct binding.
Based on the ability of WFS1 to regulate ATF6α protein, as well 
as its function in stabilizing HRD1, it followed that WFS1 may be 
recruiting ATF6α to HRD1 and that ATF6α is a substrate of HRD1. 
Indeed, HRD1 interacted with ATF6α (Figure 6A). In glycerol-gradi-
ent fractionation experiments of ER-isolated lysates, HRD1, ATF6α, 
and WFS1 were found to form a complex (Supplemental Figure 13). 
We next analyzed the interaction between ATF6α and HRD1 under 
ER stress conditions. ATF6α was released from HRD1 by DTT and 
thapsigargin treatments (Figure 6B), which indicates that the inter-
action between these proteins is disrupted by ER stress. To study the 
relationship between HRD1 and ATF6α protein expression levels, 
the stability of ATF6α protein was measured in MIN6 cells stably 
expressing shRNA directed against HRD1 and control cells. HRD1 
suppression in cells enhanced ATF6α protein stability (Figure 6C). 
In contrast, overexpression of HRD1 enhanced ATF6α protein deg-
radation (Figure 6D). HRD1 also enhanced ATF6α ubiquitination, 
and lack of HRD1 decreased ATF6α ubiquitination (Figure 6, E and 
F). Collectively, these results indicate that the WFS1-HRD1 complex 
enhances ATF6α ubiquitination and degradation.
Discussion
In this study, we provide evidence that WFS1 plays a crucial role in 
regulating ATF6α transcriptional activity through HRD1-mediated 
Figure 4
WFS1 forms a complex with the proteasome and ATF6α. (A) WFS1 was subjected to IP from INS1 832/13 cells using an anti-WFS1 specific 
antibody. IPs were subjected to IB with anti–alpha 5 20S proteasome and anti-WFS1 antibodies. (B) IB analysis measuring CREB, actin, and 
PDI levels using whole cell lysates or ER-isolated lysates of INS1 832/13 cells. ER-isolated lysates of INS1 832/13 cells were also subjected 
to fractionation using a 10%–40% glycerol gradient. Fractions were analyzed by IB using anti–alpha 5 20s proteosome, anti-ATF6α, and anti-
WFS1 antibodies. Lanes were run on separate gels and were not contiguous. (C) WFS1 was subjected to IP from a mixture of fractions 10 and 
11 using an anti-WFS1 antibody, and IP products were subjected to IB analysis using anti-alpha 5 20s proteosome, anti-ATF6α, and anti-WFS1 
antibodies. ATF6 was subjected to IP from a mixture of fractions 9 and 12, and IP products were analyzed by IB with anti–alpha 5 20s proteo-
some and anti-ATF6α (n = 3).
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ubiquitination and proteasome-mediated degradation of ATF6α 
protein. Based upon the data provided, we propose a pathway for 
the negative-feedback regulation of the ER stress signaling network 
by WFS1 (Figure 7). In healthy cells, WFS1 prevents dysregulated 
ER stress signaling by recruiting ATF6α to HRD1 and the protea-
some for ubiquitin-mediated degradation under non–ER stress 
conditions. When stress is applied to the ER, such as through the 
chemical ER stress inducer DTT, ATF6α is released from WFS1. 
It is then released from the ER membrane and translocates to the 
nucleus, where it upregulates stress signaling targets. At later time 
points, WFS1 is induced by ER stress, causing eventual degradation 
of ATF6α when ER homeostasis is established. In patients with 
Figure 5
WFS1 interacts with and stabilizes the E3 ligase HRD1. (A) Hrd1 was subjected to IP from INS1 832/13 cells, and IPs were subjected to IB 
analysis using anti-WFS1 and anti-Hrd1 antibodies (n = 3). (B) Total lysates from INS1 832/13 cells inducibly expressing shWFS1 (treated with 
2 μM doxycycline for 48 hours) were analyzed by IB using anti-WFS1, anti-Hrd1, and anti-actin antibodies (n = 3). (C) IB analysis measuring 
HRD1 levels in MIN6 cells stably expressing shGFP (control) or shWFS1 treated with 40 μM cycloheximide for 0, 0.5, 1, and 2 hours (n = 3). (D) 
Wfs1–/– and WT littermate mouse pancreata were analyzed by immunohistochemistry using anti-HRD1 and anti-insulin antibodies (n = 3). Scale 
bars: 100 μm. (E) COS7 cells were transfected with pcDNA3, HRD1–c-Myc, HRD1–c-Myc and WT WFS1, or HRD1–c-Myc and WFS1 mutants 
(P724L, G695V, and ins483fs/ter544) expression plasmids. Expression levels of HRD1–c-Myc, WFS1, and actin were measured by IB using 
anti–c-Myc, anti-WFS1, and anti-actin antibodies, respectively. WT and mutant WFS1 are denoted by single and double asterisks, respectively. 
(F) COS7 cells were transfected with pcDNA3, HRD1–c-Myc, HRD1–c-Myc and WT WFS1-Flag, HRD1–c-Myc and WFS P724L-Flag, and 
HRD1–c-Myc and WFS1 G695V-Flag expression plasmids. The lysates were subjected to IP with anti-Flag antibody and IB with anti–c-Myc 
antibody to study the interaction between HRD1 and WFS1.
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Wolfram syndrome or Wfs1–/– mice, ATF6α escapes from this pro-
teasome-dependent degradation, leading to dysregulated ATF6α 
signaling. This ATF6α hyperactivation caused by the lack of WFS1 
is probably involved in β cell apoptosis.
It has previously been shown that WFS1-deficient β cells are 
susceptible to ER stress–mediated apoptosis (11, 18, 29). We con-
firmed that knockdown of WFS1 made β cells sensitive to ER 
stress–mediated cell death (Supplemental Figure 14). In addition, 
we found that ectopic expression of an active form of ATF6α in β 
cells caused apoptosis (Supplemental Figure 15). Although this fits 
to our model that hyperactivation of ATF6α has a harmful effect on 
β cells and leads to apoptosis, it may be contrary to previous studies 
showing beneficial effects of ATF6α upregulation. For example, it 
has been shown that activation of the ATF6α pathway by a chemi-
cal compound protects neuronal cells from ER stress–mediated 
apoptosis (30). This effect is mediated by BiP upregulation. The 
induction of ATF6α has also been shown to protect cardiomyocytes 
from ischemia/reperfusion-mediated apoptosis (31). This effect is 
also mediated by BiP and GRP94 upregulation. Conversely, a recent 
report has shown that ATF6α upregulation attenuates diet-induced 
obesity and insulin resistance (32). More importantly, it has been 
shown that WT mice are better protected from ER stress in vivo 
than are ATF6α knockout mice. ATF6α knockout hepatocytes have 
been shown to be more sensitive to ER stress–mediated cell death 
compared with control hepatocytes (7). It is not surprising that pre-
vious studies found induction of ATF6α to have beneficial effects 
on cell function and cell survival, because ATF6α is a major regu-
lator for BiP, a central molecular chaperone in the ER (7, 8). The 
main conclusion of the present study is that chronic dysregulation 
of the UPR, more specifically hyperactivation of ATF6α signaling, 
has a negative effect on β cell survival. It has been suggested that 
the UPR regulates both adaptive and apoptotic effectors (2, 33). 
The balance between these effectors depends on the nature of the 
ER stress, whether it is tolerable or unresolvable. Thus, the UPR 
Figure 6
HRD1 is an E3 ligase for ATF6α. (A) HRD1 
was subjected to IP from INS1 832/13 cells 
treated for 3 hours with 30 μM MG132. IPs 
and input proteins were analyzed by IB 
using anti-ATF6α and anti-HRD1 antibod-
ies. Lanes were run on the same gel but 
were noncontiguous (white line). (B) An anti-
HRD1 antibody was used to IP HRD1 protein 
from INS1 832/13 cells untreated or treated 
with DTT (1 mM) and thapsigargin (Tg; 1 μM) 
for 3 hours. IPs were then subjected to IB 
analysis using anti-ATF6α, anti-HRD1, and 
anti-actin antibodies (n = 3). (C) IB analysis 
measuring ATF6α levels in MIN6 cells sta-
bly expressing shGFP (control) or shRNA 
shHRD1 treated with 40 μM cycloheximide 
for 0, 4, and 6 hours (n = 3). (D) COS7 cells 
transfected with ATF6α-HA expression 
plasmid (control) or ATF6α-HA together 
with Hrd1-myc expression plasmids (Hrd1) 
were treated with 40 μM cycloheximide for 
0, 4, and 6 hours. Whole cell lysates were 
subjected to IB with an anti-HA antibody 
(n = 3). (E) ATF6α was subjected to IP using 
an anti-ATF6α antibody from INS1 832/13 
cells either mock transfected (control) or 
transfected with a Hrd1-Myc expression 
plasmid and treated with MG132 (20 μM) for 
3 hours. IPs were then subjected to IB with 
anti-ubiquitin and anti-ATF6α antibodies, and 
input lysates were blotted with anti-ATF6α, 
anti–c-Myc, and anti-actin antibodies (n = 3). 
(F) ATF6 was subjected to IP using an anti-
ATF6α antibody from MIN6 cells stably 
expressing shGFP (control) or shHRD1 and 
treated with MG132 (20 μM) for 3 hours. IPs 
were then subjected to IB with anti-ubiquitin 
and anti-ATF6α antibodies, and input lysates 
were blotted with anti-HRD1, anti-ATF6α, 
and anti-actin antibodies (n = 3).
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acts as a binary switch between life and death. Our results demon-
strated that, in patients with Wolfram syndrome and Wfs1–/– mice, 
unresolvable ER stress occurs in β cells and neurons, leading to a 
switch toward apoptosis.
ER stress is caused by both physiological and pathological stim-
uli that can lead to the accumulation of unfolded and misfolded 
proteins in the ER. Physiological ER stress can be caused by a large 
biosynthetic load placed on the ER, for example, during postpran-
dial stimulation of proinsulin biosynthesis in pancreatic β cells. 
This stimulation leads to the activation of ER stress signaling and 
enhancement of insulin synthesis (34). Under physiological ER 
stress conditions, activation of ER stress signaling must be tightly 
regulated because hyperactivation or chronic activation of this sig-
naling pathway can cause cell death. For example, when eukaryotic 
translation initiation factor 2α, a downstream component of ER 
stress signaling, is hyperphosphorylated by the compound salu-
brinal in pancreatic β cells, apoptosis is induced in these cells (35). 
Our results showed that WFS1 has an important function in the 
tight regulation of ER stress signaling through its interaction with 
a key transcription factor, ATF6α, thereby protecting cells from the 
damaging effects of hyperactivation of this signaling pathway.
On the basis of our present results, we believe WFS1 plays a 
similar role in mammals as HRD3 does in yeast: stabilizing and 
enhancing the activity of a key ER-resident E3 ligase, HRD1 
(28). Thus, a loss of functional WFS1 may affect ER stress 
levels in 2 ways: (a) enhancing ATF6α signaling by increas-
ing the pool of ATF6α, and (b) destabilizing HRD1 protein 
and thus its activity. The latter would independently con-
tribute to ER stress by promoting the buildup of unfolded 
and misfolded proteins in the ER. In support of this is 
our present finding that silencing of HRD1 in β cell lines 
indeed led to mild ER stress (Supplemental Figure 16). 
It has previously been shown that HRD1 is regulated by 
the IRE1–XBP-1 pathway (26) and is activated at a later 
time point during ER stress. The ATF6α pathway, how-
ever, is activated at an earlier phase (36). Thus, WFS1 may 
also function as a switch from the ATF6α pathway to the 
IRE1–XBP-1 pathway, through the stabilization of HRD1 
and consequent destruction of ATF6α protein. A previous 
publication has reported that WFS1 deficiency could lead 
to increased HRD1 expression (17), contrary to our find-
ings. This discrepancy could be attributed to the fact that 
WFS1 deficiency can cause dysregulated ER stress signaling 
and can lead to hyperactivation of the IRE1–XBP-1 path-
way under some circumstances.
It has been established that WFS1 is induced under ER stress 
(11). However, WFS1 increased steadily over a 24-hour time peri-
od (data not shown). ATF6α upregulation, on the other hand, 
occurred much more rapidly. Thus, the initial pool of WFS1 protein 
induced under stress may not have an inhibitory effect on ATF6α 
protein. In addition, we have shown that the ER-resident chap-
erone BiP also bound to ATF6α. The release of BiP from ATF6α 
when unfolded/misfolded proteins accumulate in the ER may be 
a key step in how ATF6α escapes WFS1-mediated proteolysis. BiP 
binding may be essential for the interaction of ATF6α and WFS1, 
and, upon release, cause a conformational change in ATF6α, lead-
ing to its consequent release from WFS1.
WFS1 is highly expressed in pancreatic β cells that are specialized 
for the production and regulated secretion of insulin to control 
blood glucose levels. In β cells, ER stress signaling needs to be tight-
ly regulated to adapt to the frequent fluctuations of blood glucose 
levels and to produce the proper amount of insulin in response to 
the need for it (34, 37). To achieve tight regulation, mammals may 
have developed WFS1 as a regulator of HRD1 function in addition 
to SEL1. Higher expression of WFS1 in β cells, therefore, prevents 
hyperactivation of ER stress signaling in these cells that are particu-
larly sensitive to disruption of ER homeostasis and dysregulation 
Figure 7
WFS1 controls steady-state levels of ATF6α protein and acti-
vation. (A) In normal cells, WFS1 recruits the ER transcription 
factor ATF6α to the E3 ligase Hrd1 under non–ER stress condi-
tions. Hrd1 marks ATF6α with ubiquitin for proteasomal degra-
dation. Under ER stress, ATF6α dissociates from WFS1 and 
undergoes proteolysis, and its soluble aminoportion, p60ATF6α, 
translocates to the nucleus, where it upregulates ER stress tar-
get genes, such as BiP, CHOP, and XBP-1. At later time points, 
WFS1 is induced by ER stress, which causes the eventual 
degradation of ATF6α. (B) In patients with Wolfram syndrome 
or Wfs1–/– mice, ATF6α escapes from the proteasome-depen-
dent degradation, leading to chronic hyperactivation of ATF6α 
signaling. This ATF6α hyperactivation is involved in apoptosis 
through apoptotic effectors of the UPR, such as CHOP.
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of the UPR. Therefore, WFS1 has a role in protecting β cells from 
death by acting as an ER stress signaling suppressor.
Mutations in the gene encoding WFS1 cause Wolfram syn-
drome, a genetic form of diabetes and neurodegeneration. It has 
been proposed that a high level of ER stress causes β cell death and 
neurodegeneration in this disorder. Collectively, our results sug-
gest that a loss-of-function mutation of WFS1 causes the instabil-
ity of an E3 ligase, HRD1, leading to the upregulation of ATF6α 
protein and hyperactivation of ATF6α signaling. Therefore, we 
predict that a loss-of-function or hypomorphic mutation of the 
WFS1, HRD1, or ATF6α genes can cause ER stress–related disor-
ders, such as diabetes, neurodegeneration, and bipolar disorder. 
Indeed, it has been shown recently that common variants in WFS1 
confer risk of type 2 diabetes (14–16), and there is a link between 
WFS1 mutations and type 1A diabetes (38, 39). It has also been 
shown that ATF6α polymorphisms and haplotypes are associated 
with impaired glucose homeostasis and type 2 diabetes (40). Exces-
sive β cell loss is a component of both type 1 and type 2 diabetes 
(41); therefore, WFS1 may have a key role in the protection of these 
cells from apoptosis through the tight regulation of ER stress sig-
naling, thereby suppressing the diabetes phenotype. In addition, 
about 60% of patients with Wolfram syndrome have some mental 
disturbance such as severe depression, psychosis, or organic brain 
syndrome, as well as impulsive verbal and physical aggression (42). 
The heterozygotes who do not have Wolfram syndrome are 26-fold 
more likely than noncarriers to have a psychiatric hospitalization 
(43). The relative risk of psychiatric hospitalization for depression 
was estimated to be 7.1 in these heterozygotes (44). Therefore, it is 
possible that dysregulation of a negative feedback loop of ER stress 
signaling may have a pathological role in psychiatric illness.
In this study, we focused on determining the physiological func-
tion of WFS1 in ER stress signaling because of its implication in 
diabetes, neurodegeneration, and bipolar disorder. We propose 
that WFS1 has a critical function in the regulation of ER stress sig-
naling and prevents secretory cells, such as pancreatic β cells, from 
dysfunction and premature death caused by hyperactivation of ER 
stress signaling through its interaction with the transcription fac-
tor ATF6α. WFS1 could therefore be a key target for prevention 
and/or therapy of ER stress–mediated diseases such as diabetes, 
neurodegenerative diseases, and bipolar disorder.
Methods
Cell culture. Rat insulinoma cells (INS1 832/13) were a gift from C. New-
gard (Duke University Medical Center, Durham, North Carolina) and 
cultured in RPMI 1640 supplemented with 10% FBS. Mouse insulinoma 
cells (MIN6) were maintained in DMEM with 15% FBS and 1% sodium 
pyruvate. COS7 and Neuro2A cells were cultured in DMEM supplemented 
with 10% FBS. For generation of cells inducibly overexpressing WFS1 and 
GFP, INS-1 832/13 cells stably expressing pTetR were transduced with a 
lentivirus expressing human WFS1-FLAG or GFP and cultured in 2 μM 
doxycycline for 24 hours prior to protein/RNA isolation. For generation of 
cells stably suppressing WFS1 or GFP, MIN6 cells were transduced with a 
retrovirus expressing shRNA against mouse WFS1 or GFP. For overexpres-
sion of ATF6, Hrd1, and WFS1, COS7 cells were transfected with ATF6-
HA and WFS1-FLAG expression plasmids using FuGENE 6 transfection 
reagent (Roche Applied Science). As a control for coexpression, equivalent 
amounts of pcDNA3 plasmid was used. DTT, cycloheximide, and MG132 
were purchased from Sigma-Aldrich.
Plasmids. ATF6 plasmids were provided by R. Prywes (Columbia Univer-
sity, New York). GRP78 reporter plasmid was provided by K. Mori (Kyoto 
University, Japan). Hrd1-myc plasmid was a gift from M. Kaneko and M. 
Nomura (Hokkaido University, Sapporo, Japan). TCRα plasmids were pro-
vided by R. Kopito (Stanford University, California), and NHK3 plasmids 
were a gift from K. Nagata (Kyoto University). Entry vectors, destination 
vectors, and viral plasmids for establishing lentiviral and retroviral cell lines 
were provided by E. Campeau (University of Massachusetts Medical School; 
ref. 45). shRNA against WFS1 and GFP were purchased from the shRNA 
Library Core Facility at the University of Massachusetts Medical School.
IB. Cells were lysed in ice-cold TNE buffer (50 mM Tris HCl, pH 7.5; 150 
mM NaCl; 1 mM EDTA; and 1% NP-40) containing a protease inhibitor 
cocktail (Sigma-Aldrich) for 15 minutes on ice. Lysates were then cleared by 
centrifuging the cells at 12,000 g for 20 minutes at 4°C. Lysates were normal-
ized for total protein (30 μg/lane), separated using a 4%–20% linear gradi-
ent SDS-PAGE (BioRad), and electroblotted. Anti-WFS1 antibody was a gift 
from Y. Oka (Tohoku University). Anti-actin and anti-FLAG antibodies were 
purchased from Sigma-Aldrich. Anti-HA antibody was purchase from Stress-
gen, and anti-ATF6 and anti-GFP antibodies were purchased from Santa 
Cruz Biotechnology. Antigen retrieval was used for the anti-ATF6 antibody. 
Anti-ubiquitin and anti-IRE1 antibodies were purchased from Cell Signal-
ing. Anti–alpha 5 20s proteasome antibody was purchased from Biomol, and 
anti-PERK antibody was purchased from Rockland Inc. Anti–c-myc antibody 
was purchased from Roche. The anti–alpha-1-antitrypsin antibody was pur-
chased from DakoCytomation. Anti-Hrd1 antibody was generated in rab-
bits using a KLH-conjugated synthetic peptide, TCRMDVLRASLPAQS. The 
antibody specificity was tested by peptide/antigen competition.
DTT chase. INS-1 832/13 cells were treated with 1 mM DTT for 2 hours. 
The DTT was washed out with normal media (RPMI 1640 supplemented 
with 10% FBS) for 0, 1, or 2 hours. Cells were lysed and subjected to IP with 
anti-WFS1 antibodies.
Fractionation. The ER was isolated from INS-1 832/13 cells using an Endo-
plasmic Reticulum Isolation kit (Sigma-Aldrich). The ER pellet was then 
lysed in ice-cold TNE buffer containing 1% NP-40 and protease inhibitors, 
and the lysates were cleared and normalized. The ER lysates (1.0 ml) were 
loaded on top of a glycerol gradient (10%–40%) prepared in PBS contain-
ing 1 mM DTT and 2 mM ATP and centrifuged at 4°C and 80,000 g for 20 
hours. We collected 32 fractions from the top of the tubes. Of each frac-
tion, 200 μl was precipitated with acetone, and the remaining pellet was 
lysed with 50 μl sample buffer. Precipitated proteins were then separated 
using a 4%–20% linear gradient SDS-PAGE and electroblotted.
IP. Cells were lysed in ice-cold TNE buffer with protease inhibitors for 
15 minutes on ice; the lysates were then cleared by centrifuging the cells at 
12,000 g for 20 minutes at 4°C. For IP of endogenous WFS1, 500 μg whole 
cell extract from each sample was incubated with Protein G Sepharose 4 
Fast Flow beads (GE Healthcare) and 4 μg anti-WFS1 antibody overnight 
at 4°C with rotation. After incubation, the beads were washed 3 times with 
TNE buffer followed by a final wash in 1× PBS. The IPs were resolved by 
SDS-PAGE and then subjected to IB. For IP of ATF6, 6 μg anti-ATF6 anti-
body was used; for HA, 2 μg anti-HA antibody was used; and for Hrd1, 4 μg 
anti-Hrd1 antibody was used. As a control, lysates were subjected to IP as 
described above using rabbit IgG.
Real-time PCR. Total RNA was isolated from the cells using the RNeasy 
Mini Kit (Qiagen) and reverse transcribed using 1 μg total RNA from 
cells with Oligo-dT primer. For the thermal cycle reaction, the iQ5 sys-
tem (BioRad) was used at 95°C for 10 minutes, then 40 cycles at 95°C 
for 10 seconds, and 55°C for 30 seconds. The relative amount for each 
transcript was calculated by a standard curve of cycle thresholds for serial 
dilutions of cDNA sample and normalized to the amount of actin. PCR 
was performed in triplicate for each sample; all experiments were repeated 
3 times. The following sets of primers and Power SYBR Green PCR Master 
Mix (Applied Biosystems) were used for real-time PCR: rat actin, GCAAAT-
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GCTTCTAGGCGGAC and AAGAAAGGGTGTAAAACGCAGC; rat BiP, 
TGGGTACATTTGATCTGACTGGA and CTCAAAGGTGACTTCAATCT-
GGG; rat Chop, AGAGTGGTCAGTGCGCAGC and CTCATTCTCCT-
GCTCCTTCTCC; rat total XBP-1, TGGCCGGGTCTGCTGAGTCCG 
and ATCCATGGGAAGATGTTCTGG; rat ERO1-α, GAGAAGCTGTA-
ATAGCCACGAGG and GAGCCTTTCAATAAGCGGACTG; rat GLUT2, 
GTGTGAGGATGAGCTGCCTAAA and TTCGAGTTAAGAGGGAGCGC; 
rat INS2, ATCCTCTGGGAGCCCCGC and AGAGAGCTTCCACCAAG.
Luciferase assay. COS7 cells were mock transfected, transfected with full-
length ATF6 or ΔATF6 with pcDNA3.0, or transfected with ATF6 with 
WFS1 expression plasmids along with rat GRP78 (ERSE) promoter lucif-
erase reporter gene, WT ATF6 binding site luciferase reporter gene (ATF-
6GL3), or mutant ATF6 binding site luciferase reporter gene (ATF6m1GL3) 
using Lipofectamine 2000 (Invitrogen). At 48 hours after transfection, 
lysates were prepared using a Luciferase Assay System kit (Promega). The 
light produced from the samples was read by a standard plate reading lumi-
nometer. Each sample was read in triplicate and normalized against the sig-
nal produced from mock wells. All experiments were repeated 3 times.
Wfs1–/– animals. Wfs1–/– mice were provided by M.A. Permutt (Washing-
ton University, St. Louis, Missouri). All procedures were reviewed and 
approved by the University of Massachusetts Medical School IACUC 
(assurance no. A-3306-01).
Statistics. To determine whether the treatment was significantly different 
from the control, 2-tailed paired Student’s t test was used. A P value less 
than 0.01 was considered statistically significant. In the figures, numbers 
below the lanes of blots denote relative protein amounts, as quantified by 
ImageJ software, normalized to the respective control. All graphical data are 
shown as mean ± SD.
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